Cargando…

Pharmacogenetic Inhibition of eIF4E-Dependent Mmp9 mRNA Translation Reverses Fragile X Syndrome-like Phenotypes

Fragile X syndrome (FXS) is the leading genetic cause of autism. Mutations in Fmr1 (fragile X mental retardation 1 gene) engender exaggerated translation resulting in dendritic spine dysmorphogenesis, synaptic plasticity alterations, and behavioral deficits in mice, which are reminiscent of FXS phen...

Descripción completa

Detalles Bibliográficos
Autores principales: Gkogkas, Christos G., Khoutorsky, Arkady, Cao, Ruifeng, Jafarnejad, Seyed Mehdi, Prager-Khoutorsky, Masha, Giannakas, Nikolaos, Kaminari, Archontia, Fragkouli, Apostolia, Nader, Karim, Price, Theodore J., Konicek, Bruce W., Graff, Jeremy R., Tzinia, Athina K., Lacaille, Jean-Claude, Sonenberg, Nahum
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4294557/
https://www.ncbi.nlm.nih.gov/pubmed/25466251
http://dx.doi.org/10.1016/j.celrep.2014.10.064
_version_ 1782352733756456960
author Gkogkas, Christos G.
Khoutorsky, Arkady
Cao, Ruifeng
Jafarnejad, Seyed Mehdi
Prager-Khoutorsky, Masha
Giannakas, Nikolaos
Kaminari, Archontia
Fragkouli, Apostolia
Nader, Karim
Price, Theodore J.
Konicek, Bruce W.
Graff, Jeremy R.
Tzinia, Athina K.
Lacaille, Jean-Claude
Sonenberg, Nahum
author_facet Gkogkas, Christos G.
Khoutorsky, Arkady
Cao, Ruifeng
Jafarnejad, Seyed Mehdi
Prager-Khoutorsky, Masha
Giannakas, Nikolaos
Kaminari, Archontia
Fragkouli, Apostolia
Nader, Karim
Price, Theodore J.
Konicek, Bruce W.
Graff, Jeremy R.
Tzinia, Athina K.
Lacaille, Jean-Claude
Sonenberg, Nahum
author_sort Gkogkas, Christos G.
collection PubMed
description Fragile X syndrome (FXS) is the leading genetic cause of autism. Mutations in Fmr1 (fragile X mental retardation 1 gene) engender exaggerated translation resulting in dendritic spine dysmorphogenesis, synaptic plasticity alterations, and behavioral deficits in mice, which are reminiscent of FXS pheno-types. Using postmortem brains from FXS patients and Fmr1 knockout mice (Fmr1 (−/y)), we show that phosphorylation of the mRNA 5′ cap binding protein, eukaryotic initiation factor 4E (eIF4E), is elevated concomitant with increased expression of matrix metalloproteinase 9 (MMP-9) protein. Genetic or pharmacological reduction of eIF4E phosphorylation rescued core behavioral deficits, synaptic plasticity alterations, and dendritic spine morphology defects via reducing exaggerated translation of Mmp9 mRNA in Fmr1 (−/y) mice, whereas MMP-9 overexpression produced several FXS-like phenotypes. These results uncover a mechanism of regulation of synaptic function by translational control of Mmp-9 in FXS, which opens the possibility of new treatment avenues for the diverse neurological and psychiatric aspects of FXS.
format Online
Article
Text
id pubmed-4294557
institution National Center for Biotechnology Information
language English
publishDate 2014
record_format MEDLINE/PubMed
spelling pubmed-42945572015-01-14 Pharmacogenetic Inhibition of eIF4E-Dependent Mmp9 mRNA Translation Reverses Fragile X Syndrome-like Phenotypes Gkogkas, Christos G. Khoutorsky, Arkady Cao, Ruifeng Jafarnejad, Seyed Mehdi Prager-Khoutorsky, Masha Giannakas, Nikolaos Kaminari, Archontia Fragkouli, Apostolia Nader, Karim Price, Theodore J. Konicek, Bruce W. Graff, Jeremy R. Tzinia, Athina K. Lacaille, Jean-Claude Sonenberg, Nahum Cell Rep Article Fragile X syndrome (FXS) is the leading genetic cause of autism. Mutations in Fmr1 (fragile X mental retardation 1 gene) engender exaggerated translation resulting in dendritic spine dysmorphogenesis, synaptic plasticity alterations, and behavioral deficits in mice, which are reminiscent of FXS pheno-types. Using postmortem brains from FXS patients and Fmr1 knockout mice (Fmr1 (−/y)), we show that phosphorylation of the mRNA 5′ cap binding protein, eukaryotic initiation factor 4E (eIF4E), is elevated concomitant with increased expression of matrix metalloproteinase 9 (MMP-9) protein. Genetic or pharmacological reduction of eIF4E phosphorylation rescued core behavioral deficits, synaptic plasticity alterations, and dendritic spine morphology defects via reducing exaggerated translation of Mmp9 mRNA in Fmr1 (−/y) mice, whereas MMP-9 overexpression produced several FXS-like phenotypes. These results uncover a mechanism of regulation of synaptic function by translational control of Mmp-9 in FXS, which opens the possibility of new treatment avenues for the diverse neurological and psychiatric aspects of FXS. 2014-11-26 2014-12-11 /pmc/articles/PMC4294557/ /pubmed/25466251 http://dx.doi.org/10.1016/j.celrep.2014.10.064 Text en © 2014 The Authors This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
spellingShingle Article
Gkogkas, Christos G.
Khoutorsky, Arkady
Cao, Ruifeng
Jafarnejad, Seyed Mehdi
Prager-Khoutorsky, Masha
Giannakas, Nikolaos
Kaminari, Archontia
Fragkouli, Apostolia
Nader, Karim
Price, Theodore J.
Konicek, Bruce W.
Graff, Jeremy R.
Tzinia, Athina K.
Lacaille, Jean-Claude
Sonenberg, Nahum
Pharmacogenetic Inhibition of eIF4E-Dependent Mmp9 mRNA Translation Reverses Fragile X Syndrome-like Phenotypes
title Pharmacogenetic Inhibition of eIF4E-Dependent Mmp9 mRNA Translation Reverses Fragile X Syndrome-like Phenotypes
title_full Pharmacogenetic Inhibition of eIF4E-Dependent Mmp9 mRNA Translation Reverses Fragile X Syndrome-like Phenotypes
title_fullStr Pharmacogenetic Inhibition of eIF4E-Dependent Mmp9 mRNA Translation Reverses Fragile X Syndrome-like Phenotypes
title_full_unstemmed Pharmacogenetic Inhibition of eIF4E-Dependent Mmp9 mRNA Translation Reverses Fragile X Syndrome-like Phenotypes
title_short Pharmacogenetic Inhibition of eIF4E-Dependent Mmp9 mRNA Translation Reverses Fragile X Syndrome-like Phenotypes
title_sort pharmacogenetic inhibition of eif4e-dependent mmp9 mrna translation reverses fragile x syndrome-like phenotypes
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4294557/
https://www.ncbi.nlm.nih.gov/pubmed/25466251
http://dx.doi.org/10.1016/j.celrep.2014.10.064
work_keys_str_mv AT gkogkaschristosg pharmacogeneticinhibitionofeif4edependentmmp9mrnatranslationreversesfragilexsyndromelikephenotypes
AT khoutorskyarkady pharmacogeneticinhibitionofeif4edependentmmp9mrnatranslationreversesfragilexsyndromelikephenotypes
AT caoruifeng pharmacogeneticinhibitionofeif4edependentmmp9mrnatranslationreversesfragilexsyndromelikephenotypes
AT jafarnejadseyedmehdi pharmacogeneticinhibitionofeif4edependentmmp9mrnatranslationreversesfragilexsyndromelikephenotypes
AT pragerkhoutorskymasha pharmacogeneticinhibitionofeif4edependentmmp9mrnatranslationreversesfragilexsyndromelikephenotypes
AT giannakasnikolaos pharmacogeneticinhibitionofeif4edependentmmp9mrnatranslationreversesfragilexsyndromelikephenotypes
AT kaminariarchontia pharmacogeneticinhibitionofeif4edependentmmp9mrnatranslationreversesfragilexsyndromelikephenotypes
AT fragkouliapostolia pharmacogeneticinhibitionofeif4edependentmmp9mrnatranslationreversesfragilexsyndromelikephenotypes
AT naderkarim pharmacogeneticinhibitionofeif4edependentmmp9mrnatranslationreversesfragilexsyndromelikephenotypes
AT pricetheodorej pharmacogeneticinhibitionofeif4edependentmmp9mrnatranslationreversesfragilexsyndromelikephenotypes
AT konicekbrucew pharmacogeneticinhibitionofeif4edependentmmp9mrnatranslationreversesfragilexsyndromelikephenotypes
AT graffjeremyr pharmacogeneticinhibitionofeif4edependentmmp9mrnatranslationreversesfragilexsyndromelikephenotypes
AT tziniaathinak pharmacogeneticinhibitionofeif4edependentmmp9mrnatranslationreversesfragilexsyndromelikephenotypes
AT lacaillejeanclaude pharmacogeneticinhibitionofeif4edependentmmp9mrnatranslationreversesfragilexsyndromelikephenotypes
AT sonenbergnahum pharmacogeneticinhibitionofeif4edependentmmp9mrnatranslationreversesfragilexsyndromelikephenotypes